Search

Your search keyword '"Catalano, Lucio"' showing total 23 results
Start Over Author "Catalano, Lucio" Topic medicine
23 results on '"Catalano, Lucio"'

1. Residual respiratory impairment after COVID-19 pneumonia

Author

Lombardi, Francesco, Calabrese, Angelo, Iovene, Bruno, Pierandrei, Chiara, Lerede, Marialessia, Varone, Francesco, Richeldi, Luca, Sgalla, Giacomo, Landi, Francesco, Gremese, Elisa, Bernabei, Roberto, Fantoni, Massimo, Gasbarrini, Antonio, Settanni, Carlo Romano, Benvenuto, Francesca, Bramato, Giulia, Carfi', Angelo, Ciciarello, Francesca, Lo Monaco, Maria Rita, Martone, Anna Maria, Marzetti, Emanuele, Carmen, Napolitano, Pagano, Francesco Cosimo, Rocchi, Sara, Rota, Elisabetta, Salerno, Andrea, Tosato, Matteo, Tritto, Marcello, Calvani, Riccardo, Catalano, Lucio, Anna, Picca, Giulia, Savera, Tamburrini, Enrica, Borghetti, Alberto, Simona Di Gianbenedetto, Murri, Rita, Cingolani, Antonella, Ventura, Giulio, Taddei, Eleonora, Davide, Moschese, Arturo, Ciccullo, Stella, Leonardo, Addolorato, Giovanni, Franceschi, Francesco, Gertrude, Mingrone, Zocco, Maria Assunta, Mauirizio, Sanguinetti, Cattani Franchi, Paola, Marchetti, Simona, Alessandro, Bizzarro, Lauria, Alessandra, Rizzo, Stanislao, Savastano, Maria Cristina, Gambini, Gloria, Maria Grazia Cozzupoli, Culiersi, Carola, Passali, Giulio Cesare, Paludetti, Gaetano, Galli, Jacopo, Crudo, Fabrizio, Giovanni Di Cintio, Ylenia, Longobardi, Laura, Tricarico, Santantonio, Mariaconsiglia, Buonsenso, Danilo, Valentini, Piero, Davide, Pata, Davide, Sinatti, De Rose, Cristina, Aangelo, Calabrese, Sani, Gabriele, Delfina, Janiri, Giulia, Giuseppin, Marzia, Molinaro, Modica, Marco, Natale, Luigi, Larici, Anna Rita, Marano, Riccardo, Annamaria, Paglionico, Petricca, Luca, Laura, Gigante, Gerlando, Natalello, Fedele, Anna Laura, Lizzio, Marco Maria, Santoliquido, Angelo, Santoro, Luca, Nesci, Antonio, and Valentina, Popolla

Subjects
Male, Pulmonary and Respiratory Medicine, Percent Predicted Total Lung Capacity, Settore M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICA, Partial Pressure, Pneumonia, Viral, Walk Test, 030204 cardiovascular system & hematology, dyspnoea, Severity of Illness Index, Pulmonary function testing, Diseases of the respiratory system, 03 medical and health sciences, PFT, 0302 clinical medicine, Percent Predicted Residual Volume, DLCO, cough, Diffusing capacity, 6MWT, Humans, Medicine, Respiratory function, Lung volumes, Aged, COVID, Carbon Monoxide, Exercise Tolerance, RC705-779, SARS-CoV-2, business.industry, Research, Settore MED/09 - MEDICINA INTERNA, COVID-19, Middle Aged, Oxygen, Residual Volume, Dyspnea, 030228 respiratory system, Respiratory failure, Anesthesia, Pulmonary Diffusing Capacity, Female, ABG, Blood Gas Analysis, business
Abstract

Introduction The novel coronavirus SARS-Cov-2 can infect the respiratory tract causing a spectrum of disease varying from mild to fatal pneumonia, and known as COVID-19. Ongoing clinical research is assessing the potential for long-term respiratory sequelae in these patients. We assessed the respiratory function in a cohort of patients after recovering from SARS-Cov-2 infection, stratified according to PaO2/FiO2 (p/F) values. Method Approximately one month after hospital discharge, 86 COVID-19 patients underwent physical examination, arterial blood gas (ABG) analysis, pulmonary function tests (PFTs), and six-minute walk test (6MWT). Patients were also asked to quantify the severity of dyspnoea and cough before, during, and after hospitalization using a visual analogic scale (VAS). Seventy-six subjects with ABG during hospitalization were stratified in three groups according to their worst p/F values: above 300 (n = 38), between 200 and 300 (n = 30) and below 200 (n = 20). Results On PFTs, lung volumes were overall preserved yet, mean percent predicted residual volume was slightly reduced (74.8 ± 18.1%). Percent predicted diffusing capacity for carbon monoxide (DLCO) was also mildly reduced (77.2 ± 16.5%). Patients reported residual breathlessness at the time of the visit (VAS 19.8, p Conclusion Approximately one month after hospital discharge, patients with COVID-19 can have residual respiratory impairment, including lower exercise tolerance. The extent of this impairment seems to correlate with the severity of respiratory failure during hospitalization.

Published
2021

2. Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization

Author

Gabrielli, Maurizio, Pignataro, Giulia, Candelli, Marcello, Sacco Fernandez, Marta, Bizzarri, Martina, Esperide, Alessandra, Franceschi, Francesco, Abbate, Valeria, Nicola, Acampora, Addolorato, Giovanni, Agostini, Fabiana, Ainora, Maria Elena, Akacha, Karim, Amato, Elena, Andreani, Francesca, Andriollo, Gloria, Annetta, Maria Giuseppina, Annicchiarico, Brigida Eleonora, Mariangela, Antonelli, Antonucci, Gabriele, Marco, Anzellotti Gian, Armuzzi, Alessandro, Baldi, Fabiana, Barattucci, Ilaria, Barillaro, Christian, Fabiana, Barone, Bellantone, Rocco Domenico Alfonso, Andrea, Bellieni, Bello, Giuseppe, Benicchi, Andrea, Benvenuto, Francesca, Berardini, Ludovica, Berloco, Filippo, Bernabei, Roberto, Bianchi, Antonio, Biasucci, Daniele Guerino, Biasucci, Luigi Marzio, Stefano, Bibbò, Bini, Alessandra, Alessandra, Bisanti, Biscetti, Federico, Bocci, Maria Grazia, Nicola, Bonadia, Bongiovanni, Filippo, Borghetti, Alberto, Bosco, Giulia, Bosello, Silvia Laura, Bove, Vincenzo, Bramato, Giulia, Brandi, Vincenzo, Teresa, Bruni, Bruno, Carmine, Bruno, Dario, Bungaro, Maria Chiara, Buonomo, Alessandro, Livia, Burzo, Angelo, Calabrese, Rosaria, Calvello Maria, Andrea, Cambieri, Cambise, Chiara, Camma, Giulia, Gennaro, Canistro, Antonello, Cantanale, Capalbo, Gennaro, Capaldi, Lorenzo, Capone, Emanuele, Capristo, Esmeralda, Carbone, Luigi, Silvia, Cardone, Carelli, Simone, Carfi', Angelo, Annamaria, Carnicelli, Caruso, Cristiano, Antonio, Casciaro Francesco, Catalano, Lucio, Cauda, Roberto, Cecchini, Andrea Leonardo, Cerrito, Lucia, Melania, Cesarano, Chiarito, Annalisa, Cianci, Rossella, Cicetti, Marta, Cicchinelli, Sara, Arturo, Ciccullo, Ciciarello, Francesca, Cingolani, Antonella, Cipriani, Maria Camilla, Consalvo, Ludovica Maria, Coppola, Gaetano, Corbo, Giuseppe Maria, Corsello, Andrea, Costante, Federico, Matteo, Costanzi, Covino, Marcello, Davide, Crupi, Lucio, Cutuli Salvatore, D'Addio, Stefano, D'Alessandro, Alessia, D'Alfonso, Maria Elena, D'Angelo, Emanuela, Francesca, D’Aversa, Damiano, Fernando, De Maria, Berardinis Gian, De Cunzo, Tommaso, De Gaetano Donati, Katleen, De Luca, Giulio, De Matteis, Giuseppe, De Pascale, Gennaro, De Paolo, Santis, De Martina, Siena, De Francesco, Vito, Del Valeria, Gatto, Del Paola, Giacomo, Del Fabio, Zompo, Maria, Dell’Anna Antonio, Della Davide, Polla, Di Luca, Gialleonardo, Di Simona, Giambenedetto, Di Roberta, Luca, Di Luca, Maurizio, Di Mariangela, Muro, Alex, Dusina, Davide, Eleuteri, Alessandra, Esperide, Daniele, Facheci, Domenico, Faliero, Cinzia, Falsiroli, Massimo, Fantoni, Annalaura, Fedele, Daniela, Feliciani, Cristina, Ferrante, Giuliano, Ferrone, Rossano, Festa, Chiara, Fiore Maria, Andrea, Flex, Evelina, Forte, Francesco, Franceschi, Alessandra, Francesconi, Laura, Franza, Barbara, Funaro, Mariella, Fuorlo, Domenico, Fusco, Maurizio, Gabrielli, Eleonora, Gaetani, Claudia, Galletta, Antonella, Gallo, Giovanni, Gambassi, Matteo, Garcovich, Antonio, Gasbarrini, Irene, Gasparrini, Silvia, Gelli, Antonella, Giampietro, Laura, Gigante, Gabriele, Giuliano, Giorgia, Giuliano, Bianca, Giupponi, Elisa, Gremese, Luca, Grieco Domenico, Manuel, Guerrera, Valeria, Guglielmi, Caterina, Guidone, Antonio, Gullì, Amerigo, Iaconelli, Aurora, Iafrati, Ianiro, Gianluca, Angela, Iaquinta, Michele, Impagnatiello, Riccardo, Inchingolo, Enrica, Intini, Raffaele, Iorio, Maria, Izzi Immacolata, Tamara, Jovanovic, Cristina, Kadhim, Rosa, La Macchia, Ignazio, La Milia Daniele, Francesco, Landi, Giovanni, Landi, Rosario, Landi, Raffaele, Landolfi, Massimo, Leo, Maria, Leone Paolo, Laura, Levantesi, Antonio, Liguori, Rosa, Liperoti, Maria, Lizzio Marco, Rita, Lo Monaco Maria, Pietro, Locantore, Francesco, Lombardi, Gianmarco, Lombardi, Loris, Lopetuso, Valentina, Loria, Raffaella, Losito Angela, Patricia, Lucia Mothanje Barbara, Francesco, Macagno, Noemi, Macerola, Giampaolo, Maggi, Giuseppe, Maiuro, Francesco, Mancarella, Francesca, Mangiola, Alberto, Manno, Debora, Marchesini, Marco, Maresca Gian, Giuseppe, Marrone, Ilaria, Martis, Maria, Martone Anna, Marzetti, Emanuele, Chiara, Mattana, Valeria, Matteo Maria, Riccardo, Maviglia, Ada, Mazzarella, Carmen, Memoli, Luca, Miele, Alessio, Migneco, Irene, Mignini, Alessandro, Milani, Domenico, Milardi, Massimo, Montalto, Giuliano, Montemurro, Flavia, Monti, Montini, Luca, Christian, Morena Tony, Vincenzina, Morra, Davide, Moschese, Ambra, Murace Celeste, Martina, Murdolo, Rita, Murri, Marco, Napoli, Elisabetta, Nardella, Gerlando, Natalello, Daniele, Natalini, Maria, Navarra Simone, Antonio, Nesci, Alberto, Nicoletti, Rocco, Nicoletti, Filippo, Nicoletti Tommaso, Rebecca, Nicolò, Nicola, Nicolotti, Celestino, Nista Enrico, Eugenia, Nuzzo, Marco, Oggiano, Veronica, Ojetti, Cosimo, Pagano Francesco, Gianfranco, Paiano, Cristina, Pais, Federico, Paolillo, Federico, Pallavicini, Andrea, Palombo, Alfredo, Papa, Domenico, Papanice, Giovanni, Papparella Luigi, Mattia, Paratore, Giuseppe, Parrinello, Giuliana, Pasciuto, Pierpaolo, Pasculli, Giovanni, Pecorini, Simone, Perniola, Erika, Pero, Luca, Petricca, Martina, Petrucci, Chiara, Picarelli, Andrea, Piccioni, Annalisa, Piccolo, Edoardo, Piervincenzi, Giulia, Pignataro, Raffaele, Pignataro, Gabriele, Pintaudi, Luca, Pisapia, Marco, Pizzoferrato, Fabrizio, Pizzolante, Roberto, Pola, Caterina, Policola, Maurizio, Pompili, Flavia, Pontecorvi, Valerio, Pontecorvi, Francesca, Ponziani, Valentina, Popolla, Enrica, Porceddu, Angelo, Porfidia, Maria, Porro Lucia, Annalisa, Potenza, Francesca, Pozzana, Giuseppe, Privitera, Daniela, Pugliese, Gabriele, Pulcini, Simona, Racco, Francesca, Raffaelli, Vittoria, Ramunno, Ludovico, Rapaccini Gian, Richeldi, Luca, Rinninella, Emanuele, Sara, Rocchi, Bruno, Romanò, Stefano, Romano, Federico, Rosa, Laura, Rossi, Raimondo, Rossi, Enrica, Rossini, Elisabetta, Rota, Fabiana, Rovedi, Carlotta, Rubino, Gabriele, Rumi, Andrea, Russo, Luca, Sabia, Andrea, Salerno, Sara, Salini, Lucia, Salvatore, Dehara, Samori, Sandroni, Claudio, Maurizio, Sanguinetti, Luca, Santarelli, Paolo, Santini, Danilo, Santolamazza, Angelo, Santoliquido, Francesco, Santopaolo, Cosimo, Santoro Michele, Francesco, Sardeo, Caterina, Sarnari, Angela, Saviano, Luisa, Saviano, Scaldaferri, Franco, Roberta, Scarascia, Tommaso, Schepis, Francesca, Schiavello, Giancarlo, Scoppettuolo, Davide, Sedda, Flaminio, Sessa, Luisa, Sestito, Carlo, Settanni, Matteo, Siciliano, Valentina, Siciliano, Rossella, Sicuranza, Benedetta, Simeoni, Jacopo, Simonetti, Andrea, Smargiassi, Maurizio, Soave Paolo, Chiara, Sonnino, Domenico, Staiti, Claudia, Stella, Leonardo, Stella, Eleonora, Stival, Eleonora, Taddei, Rossella, Talerico, Elio, Tamburello, Enrica, Tamburrini, Sofia, Tanzarella Eloisa, Elena, Tarascio, Claudia, Tarli, Alessandra, Tersali, Pietro, Tilli, Jacopo, Timpano, Enrico, Torelli, Flavia, Torrini, Matteo, Tosato, Alberto, Tosoni, Luca, Tricoli, Marcello, Tritto, Mario, Tumbarello, Maria, Tummolo Anita, Sole, Vallecoccia Maria, Federico, Valletta, Francesco, Varone, Francesco, Vassalli, Giulio, Ventura, Lucrezia, Verardi, Lorenzo, Vetrone, Giuseppe, Vetrugno, Elena, Visconti, Felicia, Visconti, Andrea, Viviani, Raffaella, Zaccaria, Carmelina, Zaccone, Lorenzo, Zelano, Lorenzo, Zileri Dal Verme, and Giuseppe, Zuccalà

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Emergency department, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19, Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO, asthma, medicine.disease, Hospitalization, Emergency medicine, CE-Research Letter to the Editor, SARS-CoV2, Emergency Medicine, Internal Medicine, medicine, Prevalence, Humans, In patient, business, Emergency Service, Hospital, Asthma, Retrospective Studies
Published
2021

3. Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service

Author

Janiri, D., Kotzalidis, G. D., Giuseppin, G., Molinaro, M., Modica, Marco, Montanari, Silvia, Terenzi, Beatrice, Carfi, A., Landi, Francesco, Sani, Gabriele, rancesco Landi, Elisa Gremese, Roberto Bernabei, Massimo Fantoni, Gasbarrini, Antonio, Settanni, Carlo Romano, Benvenuto, Francesca, Bramato, Giulia, Brandi, Vincenzo, Carfi', Angelo, Ciciarello, Francesca, Rita, M., Lo Monaco, Andrea, Martone, Anna Maria, Marzetti, Emanuele, Carmennapolitano, Pagano, Francesco Cosimo, Rocchi, Sara, Elisabettarota, Salerno, Andrea, Tosato, Matteo, Tritto, Marcello, Calvani, Riccardo, Catalano, Lucio, Anna, Picca, Savera, Giulia, Cauda, Roberto, Tamburrini, Enrica, Borghetti, Alberto, Simona Di Gianbenedetto, Murri, Rita, Cingolani, Antonella, Ventura, Giulio, Taddei, Eleonora, Davide, Moschese, Arturo, Ciccullo, Stella, Leonardo, Addolorato, Giovanni, Franceschi, Francesco, Mingrone, Geltrude, Zocco, Maria Assunta, Sanguinetti, Maurizio, Cattani Franchi, Paola, Marchetti, Simona, Posteraro, Brunella, Sali, Michela, Bizzarro, Alessandra, Lauria, Alessandra, Rizzo, Stanislao, Savastano, Maria Cristina, Gambini, Gloria, Grazia Maria Cozzupoli, Culiersi, Carola, Passali, Giulio Cesare, Paludetti, Gaetano, Galli, Jacopo, D'Alatri, Lucia, Crudo, Fabrizio, Giovanni Di Cintio, Longobardi, Ylenia, Laura, Tricarico, Santantonio, Mariaconsiglia, Buonsenso, Danilo, Valentini, Piero, Davide, Pata, Sinatti, Dario, De Rose, Cristina, Richeldi, Luca, Lombardi, Francesco, Angelo, Calabrese, Delfina, Janiri, Giulia, Giuseppin, Marzia, Molinaro, Natale, Luigi, Annrita, Larici, Marano, Riccardo, Annamaria, Paglionico, Petricca, Luca, Laura, Gigante, Gerlando, Natalello, Fedele, Anna Laura, Lizzio, Marco Maria, Tolusso, Barbara, Alivernini, Stefano, Santoliquido, Angelo, Santoro, Luca, Nesci, Antonio, Valentina, Popolla, Mari, Giorgia, Marchese, Maria Raffaella, and Ausili Cefaro, Carolina

Subjects
Affective temperaments, Coronavirus disease 2019 (COVID-19), lcsh:RC435-571, media_common.quotation_subject, Exploratory research, Disease, 03 medical and health sciences, 0302 clinical medicine, psychological distress, lcsh:Psychiatry, Medicine, emotional dysregulation, Original Research, media_common, affective temperaments, Psychiatry, nasal swab, business.industry, Settore MED/30 - MALATTIE APPARATO VISIVO, aging, Settore MED/09 - MEDICINA INTERNA, Psychological distress, COVID-19, Emotional dysregulation, Mental health, nasopharyngeal swab, 030227 psychiatry, Psychiatry and Mental health, Temperament, business, 030217 neurology & neurosurgery, Clinical psychology
Abstract

To study the long-term psychological effects of Covid-19 disease, we recruited 61 patients older than 60 years of age and administered the Kessler questionnaire K10 to assess psychological distress and classify them according to mental health risk groups. Patients' affective temperaments were assessed with the 39-item form of the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego (TEMPS-A-39) and emotional dysregulation with the Difficulties in Emotion Regulation Scale (DERS). Patients were divided in two samples according to their scores on the K10, i.e., a high likelihood of psychological distress group (N = 18) and a low likelihood of psychological distress group (N = 43). The two groups differed on their gender composition, in that more women (N = 11) were in the former and more men in the latter (N = 29) (χ2 = 4.28; p = 0.039). The high likelihood of psychological distress group scored higher on the Cyclothymic (3.39 ± 3.45 vs. 0.93 ± 1.08, p < 0.001) and the Depressive (2.28 ± 2.82 vs. 0.65 ± 1.09, p = 0.01) affective temperaments of the TEMPS and on the lack of Impulse control (12.67 ± 4.04 vs. 9.63 ± 3.14, p = 0.003) and lack of Clarity (15.00 ± 5.56 vs. 9.85 ± 4.67, p = 0.004) scales of the DERS. Our results show that having had Covid-19 may be related with high likelihood for psychological distress in advanced-age people and this may in turn be associated with impaired emotional regulation and higher scores on depressive and cyclothymic temperaments.

Published
2020

4. Assessment of neurological manifestations in hospitalized patients with COVID-19

Author

Luigetti, M., Iorio, R., Bentivoglio, A. R., Tricoli, L., Riso, V., Marotta, J., Piano, C., Primiano, G., Zileri Del Verme, L., Lo Monaco, M. R., Calabresi, P., Abbate, Valeria, Acampora, Nicola, Addolorato, Giovanni, Agostini, Fabiana, Ainora, Maria Elena, Akacha, Karim, Amato, Elena, Andreani, Francesca, Andriollo, Gloria, Annetta, Maria Giuseppina, Annicchiarico, Brigida Eleonora, Antonelli, Mariangela, Antonucci, Gabriele, Anzellotti, Gian Marco, Armuzzi, Alessandro, Baldi, Fabiana, Barattucci, Ilaria, Barillaro, Christian, Barone, Fabiana, Bellantone, Rocco Domenico Alfonso, Bellieni, Andrea, Bello, Giuseppe, Benicchi, Andrea, Benvenuto, Francesca, Berardini, Ludovica, Berloco, Filippo, Bernabei, Roberto, Bianchi, Antonio, Biasucci, Daniele Guerino, Biasucci, Luigi Marzio, Bibbò, Stefano, Bini, Alessandra, Bisanti, Alessandra, Biscetti, Federico, Bocci, Maria Grazia, Bonadia, Nicola, Bongiovanni, Filippo, Borghetti, Alberto, Bosco, Giulia, Bosello, Silvia, Bove, Vincenzo, Bramato, Giulia, Brandi, Vincenzo, Bruni, Teresa, Bruno, Carmine, Bruno, Dario, Bungaro, Maria Chiara, Buonomo, Alessandro, Burzo, Livia, Calabrese, Angelo, Calvello, Maria Rosaria, Cambieri, Andrea, Cambise, Chiara, Cammà, Giulia, Candelli, Marcello, Canistro, Gennaro, Cantanale, Antonello, Capalbo, Gennaro, Capaldi, Lorenzo, Capone, Emanuele, Capristo, Esmeralda, Carbone, Luigi, Cardone, Silvia, Carelli, Simone, Carfì, Angelo, Carnicelli, Annamaria, Caruso, Cristiano, Casciaro, Francesco Antonio, Catalano, Lucio, Cauda, Roberto, Cecchini, Andrea Leonardo, Cerrito, Lucia, Cesarano, Melania, Chiarito, Annalisa, Cianci, Rossella, Cicchinelli, Sara, Ciccullo, Arturo, Cicetti, Marta, Ciciarello, Francesca, Cingolani, Antonella, Cipriani, Maria Camilla, Consalvo, Maria Ludovica, Coppola, Gaetano, Corbo, Giuseppe Maria, Corsello, Andrea, Costante, Federico, Costanzi, Matteo, Covino, Marcello, Crupi, Davide, Cutuli, Salvatore Lucio, DAddio, Stefano, DAlessandro, Alessia, DAlfonso, Maria Elena, DAngelo, Emanuela, DAversa, Francesca, Damiano, Fernando, De Berardinis, Gian Maria, De Cunzo, Tommaso, De Gaetano, Donati Katleen, De Luca, Giulio, De Matteis, Giuseppe, De Pascale, Gennaro, De Santis, Paolo, De Siena, Martina, De Vito, Francesco, Del Gatto, Valeria, Del Giacomo, Paola, Del Zompo, Fabio, DellAnna, Antonio Maria, Della, Polla Davide, Di Gialleonardo, Luca, Di Giambenedetto, Simona, Di Luca, Roberta, Di Maurizio, Luca, Di Muro, Mariangela, Dusina, Alex, Eleuteri, Davide, Esperide, Alessandra, Fachechi, Daniele, Faliero, Domenico, Falsiroli, Cinzia, Fantoni, Massimo, Fedele, Annalaura, Feliciani, Daniela, Ferrante, Cristina, Ferrone, Giuliano, Festa, Rossano, Fiore, Maria Chiara, Flex, Andrea, Forte, Evelina, Franceschi, Francesco, Francesconi, Alessandra, Franza, Laura, Funaro, Barbara, Fuorlo, Mariella, Fusco, Domenico, Gabrielli, Maurizio, Gaetani, Eleonora, Galletta, Claudia, Gallo, Antonella, Gambassi, Giovanni, Garcovich, Matteo, Gasbarrini, Antonio, Gasparrini, Irene, Gelli, Silvia, Giampietro, Antonella, Gigante, Laura, Giuliano, Gabriele, Giuliano, Giorgia, Giupponi, Bianca, Gremese, Elisa, Grieco, Domenico Luca, Guerrera, Manuel, Guglielmi, Valeria, Guidone, Caterina, Gullì, Antonio, Iaconelli, Amerigo, Iafrati, Aurora, Ianiro, Gianluca, Iaquinta, Angela, Impagnatiello, Michele, Inchingolo, Riccardo, Intini, Enrica, Iorio, Raffaele, Izzi, Immacolata Maria, Jovanovic, Tamara, Kadhim, Cristina, La Macchia, Rosa, La Milia, Daniele Ignazio, Landi, Francesco, Landi, Giovanni, Landi, Rosario, Landolfi, Raffaele, Leo, Massimo, Leone, Paolo Maria, Levantesi, Laura, Liguori, Antonio, Liperoti, Rosa, Lizzio, Marco Maria, Lo Monaco Maria, Rita, Locantore, Pietro, Lombardi, Francesco, Lombardi, Gianmarco, Lopetuso, Loris, Loria, Valentina, Losito, Angela Raffaella, Lucia, Mothanje Barbara Patricia, Macagno, Francesco, Macerola, Noemi, Maggi, Giampaolo, Maiuro, Giuseppe, Mancarella, Francesco, Mangiola, Francesca, Manno, Alberto, Marchesini, Debora, Maresca, Gian Marco, Marrone, Giuseppe, Martis, Ilaria, Martone, Anna Maria, Marzetti, Emanuele, Mattana, Chiara, Matteo, Maria Valeria, Maviglia, Riccardo, Mazzarella, Ada, Memoli, Carmen, Miele, Luca, Migneco, Alessio, Mignini, Irene, Milani, Alessandro, Milardi, Domenico, Montalto, Massimo, Montemurro, Giuliano, Monti, Flavia, Montini, Luca, Morena, Tony Christian, Morra, Vincenzina, Morretta, Chiara, Moschese, Davide, Murace, Celeste Ambra, Murdolo, Martina, Murri, Rita, Napoli, Marco, Nardella, Elisabetta, Natalello, Gerlando, Natalini, Daniele, Navarra, Simone Maria, Nesci, Antonio, Nicoletti, Alberto, Nicoletti, Rocco, Nicoletti, Tommaso Filippo, Nicolò, Rebecca, Nicolotti, Nicola, Nista, Enrico Celestino, Nuzzo, Eugenia, Oggiano, Marco, Ojetti, Veronica, Pagano, Francesco Cosimo, Paiano, Gianfranco, Pais, Cristina, Pallavicini, Federico, Palombo, Andrea, Paolillo, Federico, Papa, Alfredo, Papanice, Domenico, Papparella, Luigi Giovanni, Paratore, Mattia, Parrinello, Giuseppe, Pasciuto, Giuliana, Pasculli, Pierpaolo, Pecorini, Giovanni, Perniola, Simone, Pero, Erika, Petricca, Luca, Petrucci, Martina, Picarelli, Chiara, Piccioni, Andrea, Piccolo, Annalisa, Piervincenzi, Edoardo, Pignataro, Giulia, Pignataro, Raffaele, Pintaudi, Gabriele, Pisapia, Luca, Pizzoferrato, Marco, Pizzolante, Fabrizio, Pola, Roberto, Policola, Caterina, Pompili, Maurizio, Pontecorvi, Flavia, Pontecorvi, Valerio, Ponziani, Francesca, Popolla, Valentina, Porceddu, Enrica, Porfidia, Angelo, Porro, Lucia Maria, Potenza, Annalisa, Pozzana, Francesca, Privitera, Giuseppe, Pugliese, Daniela, Pulcini, Gabriele, Racco, Simona, Raffaelli, Francesca, Ramunno, Vittoria, Rapaccini, Gian Ludovico, Richeldi, Luca, Rinninella, Emanuele, Rocchi, Sara, Romanò, Bruno, Romano, Stefano, Rosa, Federico, Rossi, Laura, Rossi, Raimondo, Rossini, Enrica, Rota, Elisabetta, Rovedi, Fabiana, Rubino, Carlotta, Rumi, Gabriele, Russo, Andrea, Sabia, Luca, Salerno, Andrea, Salini, Sara, Salvatore, Lucia, Samori, Dehara, Sandroni, Claudio, Sanguinetti, Maurizio, Santarelli, Luca, Santini, Paolo, Santolamazza, Danilo, Santoliquido, Angelo, Santopaolo, Francesco, Santoro, Michele Cosimo, Sardeo, Francesco, Sarnari, Caterina, Saviano, Angela, Saviano, Luisa, Scaldaferri, Franco, Scarascia, Roberta, Schepis, Tommaso, Schiavello, Francesca, Scoppettuolo, Giancarlo, Sedda, Davide, Sessa, Flaminio, Sestito, Luisa, Settanni, Carlo, Siciliano, Matteo, Siciliano, Valentina, Sicuranza, Rossella, Simeoni, Benedetta, Simonetti, Jacopo, Smargiassi, Andrea, Soave, Paolo Maurizio, Sonnino, Chiara, Staiti, Domenico, Stella, Claudia, Stella, Leonardo, Stival, Eleonora, Taddei, Eleonora, Talerico, Rossella, Tamburello, Elio, Tamburrini, Enrica, Tanzarella, Eloisa Sofia, Tarascio, Elena, Tarli, Claudia, Tersali, Alessandra, Tilli, Pietro, Timpano, Jacopo, Torelli, Enrico, Torrini, Flavia, Tosato, Matteo, Tosoni, Alberto, Tricoli, Luca, Tritto, Marcello, Tumbarello, Mario, Tummolo, Anita Maria, Vallecoccia, Maria Sole, Valletta, Federico, Varone, Francesco, Vassalli, Francesco, Ventura, Giulio, Verardi, Lucrezia, Vetrone, Lorenzo, Vetrugno, Giuseppe, Visconti, Elena, Visconti, Felicia, Viviani, Andrea, Zaccaria, Raffaella, Zaccone, Carmelina, Zelano, Lorenzo, Zileri Dal Verme, Lorenzo, and Zuccalà, Giuseppe

Subjects
Male, Hospitalized patients, muscle, Settore M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICA, neurological disorders, 0302 clinical medicine, Hyposmia, 030212 general & internal medicine, Respiratory system, education.field_of_study, Brain Diseases, Headache, virus diseases, Neuromuscular Diseases, Middle Aged, Hospitalization, medicine.anatomical_structure, Neurology, Female, medicine.symptom, Adult, medicine.medical_specialty, SARS‐CoV2, Coronavirus disease 2019 (COVID-19), Patients, Short Communication, Anosmia, precision medicine, Population, Encephalopathy, Short Communications, Clinical Neurology, Settore MED/26, 03 medical and health sciences, COVID‐19, Internal medicine, Throat, Influenza, Human, medicine, Humans, education, Aged, Retrospective Studies, business.industry, SARS-CoV-2, COVID-19, Hypoxia (medical), medicine.disease, respiratory tract diseases, body regions, Neurology (clinical), Nervous System Diseases, business, 030217 neurology & neurosurgery
Abstract

Background and purpose The objective of this study was to assess the neurological manifestations in a series of consecutive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients, comparing their frequency with a population hospitalized in the same period for flu/respiratory symptoms, finally not related to SARS-CoV-2. Methods Patients with flu/respiratory symptoms admitted to Fondazione Policlinico Gemelli hospital from 14 March 2020 to 20 April 2020 were retrospectively enrolled. The frequency of neurological manifestations of patients with SARS-CoV-2 infection was compared with a control group. Results In all, 213 patients were found to be positive for SARS-CoV-2, after reverse transcriptase polymerase chain reaction on nasal or throat swabs, whilst 218 patients were found to be negative and were used as a control group. Regarding central nervous system manifestations, in SARS-CoV-2-positive patients a higher frequency of headache, hyposmia and encephalopathy always related to systemic conditions (fever or hypoxia) was observed. Furthermore, muscular involvement was more frequent in SARS-CoV-2 infection. Conclusions Patients with COVID-19 commonly have neurological manifestations but only hyposmia and muscle involvement seem more frequent compared with other flu diseases.

Published
2020

5. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

Author

Valerio De Stefano, Lucio Catalano, Lucia Pantani, Pellegrino Musto, Elena Rossi, Enrica Antonia Martino, Antonetta Pia Falcone, Ernesto Vigna, Iolanda Vincelli, Salvatore Palmieri, Paola Tacchetti, Fortunato Morabito, Sara Bringhen, Giovanni Tripepi, Maria Teresa Petrucci, Serena Rocchi, Bruno Garibaldi, Vincenzo Pavone, Francesco Di Raimondo, Giuliana Farina, Nicola Cascavilla, Monica Galli, Antonino Neri, Stelvio Ballanti, Silvia Mangiacavalli, Maurizio Musso, Ilaria Rizzello, Ferdinando Frigeri, Massimo Offidani, Clotilde Cangialosi, Massimo Gentile, Antonella Bruzzese, Elena Zamagni, Anna Mele, Cirino Botta, Mario Boccadoro, Daniele Derudas, Marialucia Barone, Nicola Di Renzo, Concetta Conticello, Giovanni Reddiconto, Roberto Ria, Michele Cavo, Giuseppe Mele, Morabito, Fortunato, Zamagni, Elena, Conticello, Concetta, Pavone, Vincenzo, Palmieri, Salvatore, Bringhen, Sara, Galli, Monica, Mangiacavalli, Silvia, Derudas, Daniele, Rossi, Elena, Ria, Roberto, Catalano, Lucio, Tacchetti, Paola, Mele, Giuseppe, Vincelli, Iolanda Donatella, Martino, Enrica Antonia, Vigna, Ernesto, Botta, Cirino, Bruzzese, Antonella, Mele, Anna, Pantani, Lucia, Rocchi, Serena, Garibaldi, Bruno, Cascavilla, Nicola, Ballanti, Stelvio, Tripepi, Giovanni, Frigeri, Ferdinando, Falcone, Antonetta Pia, Cangialosi, Clotilde, Reddiconto, Giovanni, Farina, Giuliana, Barone, Marialucia, Rizzello, Ilaria, Musto, Pellegrino, De Stefano, Valerio, Musso, Maurizio, Petrucci, Maria Teresa, Offidani, Massimo, Neri, Antonino, Di Renzo, Nicola, Di Raimondo, Francesco, Boccadoro, Mario, Cavo, Michele, and Gentile, Massimo

Subjects
Oncology, medicine.medical_specialty, Salvage therapy, Antibodies, Monoclonal, Humanized, Dexamethasone, Settore MED/15 - Malattie Del Sangue, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Elotuzumab, Lenalidomide, Multiple myeloma, Retrospective Studies, Salvage Therapy, carfilzomib, business.industry, Hazard ratio, Hematology, General Medicine, medicine.disease, Carfilzomib, elotuzumab, multiple myeloma, chemistry, Cohort, business, Oligopeptides, medicine.drug
Abstract

The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared with EloRd cohort. Moreover, cytogenetic risk categories, detected in roughly one-third of cases, were equally distributed between the two therapy arms. The probability of CR+VGPR response was significantly higher in KRd (n = 314, 53.9%) than in EloRd patients (n = 111, 37.0%). Likewise, the cumulative incidence function of CR+VGPR, taking into account the competitive risk of death, was significantly higher in KRd arm patients than those in the EloRd arm (p = .003). Moreover, KRd treatment significantly reduced the progression or death risk by 46% in an adjusted multivariate analysis (HR: 0.54, 95% CI 0.42-0.69, p .0001). Finally, in an adjusted illness-progression/death model, the effect of KRd versus EloRd was of higher magnitude among those who achieved CR+VGPR (-39% hazard ratio reduction, p = .02) than among those who achieved VGPR (-29% hazard ratio reduction, p = .007). With limitations characteristic to any retrospective analysis, this current clinical practice study's overall results demonstrated potential benefits of KRd therapy compared with EloRd. This observation may help the daily clinical practice.

Published
2021

6. An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia

Author

Sonia Ronconi, Giovanni Martinelli, Giorgia Simonetti, Lucio Catalano, Nicoletta Marra, Sara Bravaccini, Marco Picardi, Ugo De Giorgi, Mauro De Nisco, Mattia Altini, Francesco Pagano, Novella Pugliese, Claudio Cerchione, Adele Bolognese, Silvana Pedatella, Andrea Ghelli Luserna di Rorà, Fabrizio Pane, Michele Manfra, Vincenzo Martinelli, Vita Dora Iula, Cerchione, Claudio, Martinelli, Giovanni, Pedatella, Silvana, De Nisco, Mauro, Pugliese, Novella, Manfra, Michele, Marra, Nicoletta, Ronconi, Sonia, De Giorgi, Ugo, Altini, Mattia, Simonetti, Giorgia, Di Rorà, Andrea Ghelli Luserna, Bravaccini, Sara, Catalano, Lucio, Dora Iula, Vita, Pagano, Francesco, Picardi, Marco, Bolognese, Adele, Pane, Fabrizio, and Martinelli, Vincenzo

Subjects
0301 basic medicine, Drug, Cancer Research, Antimetabolites, Antineoplastic, medicine.drug_class, media_common.quotation_subject, Drug Storage, Fungal contamination, Vial, Antimetabolite, Drug Costs, Medication Adherence, 03 medical and health sciences, 0302 clinical medicine, Drug Stability, Cost Savings, Pharmaceutical Preparations, acute leukemia,cytarabine, supportive care, Medicine, Humans, Pharmacology (medical), acute leukemia, Patient compliance, Nuclear Magnetic Resonance, Biomolecular, Chromatography, High Pressure Liquid, media_common, Pharmacology, Acute leukemia, Clinical Report, business.industry, Cytarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Solutions, supportive care, Leukemia, Myeloid, Acute, 030104 developmental biology, Oncology, Drug Package, 030220 oncology & carcinogenesis, Anesthesia, business, medicine.drug
Abstract

Cytarabine, the 4-amino-1-(β-D-arabinofuranosyl)-2(1H)-pyrimidinone, (ARA-C) is an antimetabolite cytidine analogue used worldwide as key drug in the management of leukaemia. As specified in the manufacturers' instructions, once the components-sterile water and cytarabine powder-are unpackaged and mixed, the solution begins to degrade after 6 hours at room temperature and 12 hours at 4°C. To evaluate how to avoid wasting the drug in short-term, low-dose treatment regimens, the reconstituted samples, stored at 25°C and 4°C, were analyzed every day of the test week by reversed-phase HPLC and high-field NMR spectroscopy. All the samples remained unchanged for the entire week, which corresponds to the time required to administer the entire commercial drug package during low-dose therapeutic regimens. The drug solution was stored in a glass container at 4°C in an ordinary freezer and drawn with sterile plastic syringes; during this period, no bacterial or fungal contamination was observed. Our findings show that an cytarabine solution prepared and stored in the original vials retains its efficacy and safety and can, therefore, be divided into small doses to be administered over more days, thus avoiding unnecessary expensive and harmful waste of the drug preparation. Moreover, patients who require daily administration of the drug could undergo the infusion at home without need to go to hospital. The stability of the aliquots would help decrease hospitalization costs.

Published
2020

7. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Author

Nicola Di Renzo, Concetta Conticello, Lucia Mastrullo, Giovanni Reddiconto, Alberto Fragasso, Daniele Scapicchio, Roberto Ria, Maria Teresa Petrucci, Gioacchino Marziano, Nicola Cascavilla, Alfredo Gagliardi, Vittorio Simeon, Silvia Mangiacavalli, Alessandro Corso, Giovanni D'Arena, Francesco Di Raimondo, Giovanna Mansueto, Lucio Catalano, Antonietta Falcone, Pellegrino Musto, Laura Cesini, Tommaso Caravita, Sara Bringhen, Giuseppe Pietrantuono, Oreste Villani, Dalila Salvatore, Mariella Genuardi, Mario Boccadoro, Musto, Pellegrino, Simeon, Vittorio, Cascavilla, Nicola, Falcone, Antonietta, Petrucci, Maria Teresa, Cesini, Laura, Di Raimondo, Francesco, Conticello, Concetta, Ria, Roberto, Catalano, Lucio, Salvatore, Dalila, Mastrullo, Lucia, Gagliardi, Alfredo, Villani, Oreste, Pietrantuono, Giuseppe, D'Arena, Giovanni, Mansueto, Giovanna, Bringhen, Sara, Genuardi, Mariella, Di Renzo, Nicola, Reddiconto, Giovanni, Fragasso, Alberto, Caravita, Tommaso, Scapicchio, Daniele, Marziano, Gioacchino, Boccadoro, Mario, Mangiacavalli, Silvia, and Corso, Alessandro

Subjects
Male, Oncology, medicine.medical_specialty, Salvage therapy, Myeloma, First relapse, Disease-Free Survival, Bortezomib, Re-treatment, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Internal medicine, medicine, Humans, Survival rate, Multiple myeloma, Aged, Retrospective Studies, Salvage Therapy, Hematology, business.industry, Female, Follow-Up Studies, Middle Aged, Multiple Myeloma, Survival Rate, Retrospective cohort study, General Medicine, medicine.disease, 030220 oncology & carcinogenesis, Observational study, business, 030215 immunology, medicine.drug
Abstract

Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15 months, while median PFS2 was 55 months. With a median follow-up of 56 months, overall survival was 94 months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.

Published
2018

8. Safety and comfort of domestic bortezomib injection in real-life experience

Author

Maria Di Perna, Anna Emanuele Pareto, Lucio Catalano, Claudio Cerchione, Irene Zacheo, Davide Nappi, Fabrizio Pane, Marco Picardi, Cerchione, Claudio, Nappi, Davide, Pareto, Anna Emanuele, Di Perna, Maria, Zacheo, Irene, Picardi, Marco, Pane, Fabrizio, and Catalano, Lucio

Subjects
Male, medicine.medical_specialty, Injections, Subcutaneous, Antineoplastic Agents, Disease, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Quality of life, medicine, Humans, Subcutaneou, Intensive care medicine, Adverse effect, Multiple myeloma, Aged, Aged, 80 and over, business.industry, Middle Aged, medicine.disease, Discontinuation, Regimen, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Concomitant, Quality of Life, Female, Safety, Multiple Myeloma, business, Supportive care, 030215 immunology, medicine.drug
Abstract

Despite novel agents, multiple myeloma is still an incurable disease, especially for elderly and frail patients, who are difficult to manage for concomitant comorbidities as the therapeutic options are limited and the response to chemotherapy is often short. We report our evaluations upon safety and efficacy of domestic subcutaneous bortezomib in elderly and frail patients candidate to bortezomib-melphalan-prednisone (VMP) regimen. We confirmed that overall incidence of adverse events, including peripheral neuropathy, was low, and in no case required admission to emergency service, contributing to reduce the rate of therapy discontinuation. These results confirm the effectiveness and safety of subcutaneous bortezomib, in a real-life-experience, and define a new possibility of safe auto-administration in a comfortable domestic setting. We suggest that domestic treatment can significantly improve the quality of life of the patients, avoiding unnecessary transfer to the hospital without reducing treatment efficacy.

Published
2018

9. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience

Author

Marco Picardi, Claudio Cerchione, Roberta Della Pepa, Maria Di Perna, Fabrizio Pane, Lucio Catalano, Novella Pugliese, Amalia De Renzo, Cerchione, Claudio, DE RENZO, Amalia, DI PERNA, Maria, Pepa, Roberta Della, Pugliese, Novella, Catalano, Lucio, Pane, Fabrizio, and Picardi, Marco

Subjects
Adult, Male, Bendamustine, medicine.medical_specialty, Filgrastim, medicine.medical_treatment, Polyethylene Glycols, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, medicine, Indolent Non-Hodgkin Lymphoma, Clinical endpoint, Bendamustine Hydrochloride, Humans, Prospective Studies, 030212 general & internal medicine, Aged, Febrile Neutropenia, Chemotherapy, business.industry, Lymphoma, Non-Hodgkin, Middle Aged, medicine.disease, Recombinant Proteins, Oncology, 030220 oncology & carcinogenesis, Immunology, Quality of Life, Female, Original Article, Rituximab, business, Febrile neutropenia, Pegfilgrastim, medicine.drug
Abstract

Background In this prospective study, the impact of granulocyte colony-stimulating factors (G-2 CSF) administered during induction treatment with bendamustine plus rituximab for indolent non- Hodgkin Llymphoma (NHL) was evaluated by comparing patients who received secondary prophylaxis with filgrastim (control group) versus. patients who received pegfilgrastim as primary prophylaxis (peg-group). The primary endpoint was the incidence rate of febrile neutropenia (FN)- related chemotherapy disruptions (regarding dose-dense and/or dose-intensity of schedule). The Ssecondary endpoint included days of hospitalization due to FN, and G-CSF-related side effects (grade ≥3 WHO toxicity criteria) in each group. Methods One hundred twenty-two: 122 consecutive patients, with untreated indolent NHL, were referred to our outpatient unit for remission induction immuno-chemotherapy with bendamustine-rituximab. During the first period, 61 patients received secondary prophylaxis with filgrastim, given “on demand” if ANC was

Published
2016

10. Longitudinal strain of left ventricular basal segments and E /e ′ ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study

Author

Giuseppe Cerciello, Agostino Buonauro, Vincenzo Schiano-Lomoriello, Bruno Trimarco, Maurizio Galderisi, Fabrizio Pane, Donato Mele, Roberta Esposito, Roberta Della Pepa, Lucio Catalano, Marco Picardi, SCHIANO LOMORIELLO, Vincenzo, Galderisi, Maurizio, Mele, Donato, Esposito, Roberta, Cerciello, Giuseppe, Buonauro, Agostino, DELLA PEPA, Roberta, Picardi, Marco, Catalano, Lucio, Trimarco, Bruno, and Pane, Fabrizio

Subjects
Male, Pathology, medicine.medical_specialty, Diastolic function, Longitudinal strain, Heart Ventricles, Population, 030204 cardiovascular system & hematology, Sensitivity and Specificity, Muscle hypertrophy, Diagnosis, Differential, Ventricular Dysfunction, Left, 03 medical and health sciences, Basal (phylogenetics), 0302 clinical medicine, Doppler tissue imaging, Left ventricular filling pressure, Elastic Modulus, Cardiac amyloidosi, Internal medicine, Image Interpretation, Computer-Assisted, medicine, Humans, Radiology, Nuclear Medicine and imaging, cardiovascular diseases, 030212 general & internal medicine, education, education.field_of_study, Ejection fraction, Receiver operating characteristic, business.industry, Amyloidosis, Reproducibility of Results, Middle Aged, Myocardial strain, medicine.disease, Cardiac amyloidosis, Echocardiography, Hypertension, Cardiology, Elasticity Imaging Techniques, Female, Hypertrophy, Left Ventricular, Cardiology and Cardiovascular Medicine, business
Abstract

Background Longitudinal strain is an early marker of left ventricular (LV) dysfunction in several cardiac diseases. Our aim was to differentiate cardiac amyloidosis (CA) at diagnosis from hypertensive LV hypertrophy (LVH) by analysis of longitudinal myocardial deformation. Methods Thirty healthy controls (C), 30 newly diagnosed, never treated hypertensives with LVH (H-LVH), and 33 patients with CA at diagnosis underwent echo Doppler including speckle tracking–based automated function imaging (AFI). Averaged peak systolic global longitudinal strain (GLS, 18 segments) and basal, middle, and apical longitudinal strain (BLS, MLS, and ALS, respectively, six segments each) were calculated. Results Left ventricular mass index, relative wall thickness, and ejection fraction did not differ between H-LVH and CA. E/e′ ratio was higher in CA than in H-LVH (P

Published
2016

11. A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide

Author

Lucio Catalano, Irene Zacheo, Davide Nappi, Maria Di Perna, Dalila Salvatore, Fabrizio Pane, Marco Picardi, Ilaria Migliaccio, Claudio Cerchione, Cerchione, Claudio, Nappi, Davide, DI PERNA, Maria, Zacheo, Irene, Migliaccio, Ilaria, Salvatore, Dalila, Picardi, Marco, Pane, Fabrizio, and Catalano, Lucio

Subjects
Bendamustine, Oncology, medicine.medical_specialty, business.industry, Case Report, pomalidomide, General Medicine, Case Reports, medicine.disease, Pomalidomide, multiple myeloma, relapsed, 03 medical and health sciences, refractory, 0302 clinical medicine, Refractory, 030220 oncology & carcinogenesis, Internal medicine, medicine, heavily pretreated, business, Multiple myeloma, 030215 immunology, medicine.drug
Abstract

Key Clinical Message In this report, we would like to highlight the efficacy of bendamustine in a heavily pretreated patient, also refractory to pomalidomide. It is conceivable that different therapy combinations in heavily treated Multiple myeloma (MM) have to be explored, without “a priori” exclusion of ancient drugs, even after failure of the ultimate pharmacological options., In this report, we would like to highlight the efficacy of bendamustine in a heavily pretreated patient, also refractory to pomalidomide. It is conceivable that different therapy combinations in heavily treated Multiple myeloma (MM) have to be explored, without “a priori” exclusion of ancient drugs, even after failure of the ultimate pharmacological options.

Published
2017

12. Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support

Author

Roberta Della Pepa, Claudio Cerchione, Amalia De Renzo, Fabrizio Pane, Maria Di Perna, Marco Picardi, Novella Pugliese, Davide Nappi, Lucio Catalano, Cerchione, Claudio, De Renzo, Amalia, Nappi, Davide, Di Perna, Maria, Pepa, Roberta Della, Pugliese, Novella, Catalano, Lucio, Pane, Fabrizio, and Picardi, Marco

Subjects
Bendamustine, medicine.medical_specialty, Filgrastim, business.industry, Hematologic Neoplasms, medicine.disease, Polyethylene Glycols, Granulocyte colony-stimulating factor, Bendamustine hydrochloride, Oncology, Internal medicine, Granulocyte Colony-Stimulating Factor, medicine, Bendamustine Hydrochloride, Humans, business, Pegfilgrastim, Febrile neutropenia, Aged, Febrile Neutropenia, medicine.drug
Published
2019

13. Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone

Author

Fabrizio Pane, Claudio Cerchione, Ilaria Migliaccio, Dalila Salvatore, Maria Di Perna, Marco Picardi, Lucio Catalano, Davide Nappi, Ilaria Peluso, Cerchione, Claudio, Catalano, Lucio, Peluso, Ilaria, Nappi, Davide, DI PERNA, Maria, Salvatore, Dalila, Migliaccio, Ilaria, Picardi, Marco, and Pane, Fabrizio

Subjects
Oncology, Bendamustine, medicine.medical_specialty, business.industry, Neutropenia, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Relapsed refractory, medicine, In patient, 030212 general & internal medicine, business, Letter to the Editor, Bortezomib/dexamethasone, Pegfilgrastim, Multiple myeloma, medicine.drug
Published
2016

14. Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series

Author

Elia Guadagno, Maurizio Iengo, Luana Marano, Antonella Miriam Di Lullo, Pasquale Capriglione, Gelsomina Mansueto, Lucio Catalano, Elena Cantone, Cantone, Elena, DI LULLO, ANTONELLA MIRIAM, Marano, Luana, Guadagno, Elia, Mansueto, Gelsomina, Capriglione, Pasquale, Catalano, Lucio, and Iengo, Maurizio

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, lcsh:Medicine, Case Report, Antineoplastic Agents, Plasma cell, Epistaxi, 03 medical and health sciences, 0302 clinical medicine, Surgical oncology, immune system diseases, hemic and lymphatic diseases, Medicine, Humans, 030223 otorhinolaryngology, Sinus, Multiple myeloma, Radiotherapy, business.industry, lcsh:R, Nasopharyngeal Neoplasms, General Medicine, Sinonasal Tract, Middle Aged, medicine.disease, Combined Modality Therapy, Survival Analysis, Surgery, Radiation therapy, medicine.anatomical_structure, Epistaxis, Treatment Outcome, 030220 oncology & carcinogenesis, Monoclonal, Disease Progression, Plasmacytoma, Female, Bone marrow, Neoplasm Recurrence, Local, business, Multiple Myeloma, Paranasal Sinus Neoplasms, Follow-Up Studies
Abstract

Background Extramedullary plasmacytoma is a rare neoplasm characterized by monoclonal proliferation of plasma cells outside bone marrow. It accounts for 4% of all non-epithelial sinonasal tumors. According to the literature, radiotherapy is the standard therapy for extramedullary plasmacytoma. However, the conversion rate of extramedullary plasmacytoma to multiple myeloma is reported to be between 11 and 33% over 10 years. The highest risk of conversion is reported during the first 2 years after diagnosis, but conversion has been noted up to 15 years after diagnosis. Once conversion to multiple myeloma is complete, less than 10% of patients will survive 10 years. Case presentation We present three cases of sinonasal extramedullary plasmacytoma who underwent radiotherapy: a 61-year-old white man, a 60-year-old white man, and a 37-year-old white woman. We found long-term survival with stable disease in all three cases. Conclusions The management of solitary extramedullary plasmacytomas of the sinonasal tract is not well established yet. However, the possibility of recurrence and progression to multiple myeloma requires a thorough follow-up protocol. Due to the absence of a standardized protocol for these tumors, we tried to design a tailored long-term follow-up scheme.

Published
2017

15. Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure

Author

Vincenzo Martinelli, Fabrizio Pane, Marco Picardi, Claudio Cerchione, Anna Emanuele Pareto, Davide Nappi, A. Romano, Lucio Catalano, Cerchione, Claudio, Nappi, Davide, Pareto, Anna E., Romano, Alessandra, Martinelli, Vincenzo, Picardi, Marco, Pane, Fabrizio, and Catalano, Lucio

Subjects
Male, renal failure, Cancer Research, medicine.medical_specialty, lenalidomide, Urology, Immunomodulation, 03 medical and health sciences, 0302 clinical medicine, 80 and over, medicine, Humans, Immunologic Factors, Pharmacology (medical), Renal Insufficiency, real-life, Progression-free survival, Adverse effect, Multiple myeloma, Aged, Retrospective Studies, Lenalidomide, Aged, 80 and over, Pharmacology, Kidney, business.industry, Therapeutic effect, Middle Aged, medicine.disease, Progression-Free Survival, multiple myeloma, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Toxicity, Female, Complication, business, 030215 immunology, medicine.drug
Abstract

Renal impairment (RI) is a relevant complication of patients affected by multiple myeloma (MM); it can be present in up to 30-35% of newly diagnosed MM and is linked to a poor outcome. However, early recognition and early treatment with novel agents can overcome the negative impact of RI and even reverse kidney damage in most cases. Lenalidomide, available as an oral compound, is an immunomodulatory drug with both antiproliferative and immunomodulatory activity that is largely used in the management of MM. Dose reduction is mandatory in RI; however, there is no theoretical assumption against the possibility that protracting the time of full standard doses can be equally effective and tolerated by patients requiring reduced doses. In this report, we describe our retrospective experience, in 18 patients, with the administration of lenalidomide 25 mg every other day for patients with MM and RI. The overall response ratio was 66.5%. More than half (61.1%) of the patients had a renal response. The median progression-free survival was 8 months (range: 3-18 months). No serious adverse event occurred during treatment, and it was never necessary to disrupt or delay treatment for toxicity. These preliminary observations point to a significant therapeutic effect of lenalidomide, at the dose of 25 mg every other day for 21 days, with logistic and economic advantages. However, these results should be validated by controlled studies involving larger numbers of patients.

Published
2018

16. Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

Author

Marco Picardi, Anna Emanuele Pareto, Lucio Catalano, Fabrizio Pane, Maria Di Perna, Claudio Cerchione, Irene Zacheo, Davide Nappi, Cerchione, Claudio, Nappi, Davide, DI PERNA, Maria, Zacheo, Irene, Pareto, ANNA EMANUELE, Picardi, Marco, Catalano, Lucio, and Pane, Fabrizio

Subjects
Bendamustine, medicine.medical_specialty, business.industry, Bortezomib, lcsh:RC633-647.5, Case Report, General Medicine, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, Surgery, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Refractory, Clinical history, 030220 oncology & carcinogenesis, Relapsed refractory, medicine, business, Bortezomib/dexamethasone, Multiple myeloma, 030215 immunology, medicine.drug
Abstract

The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced phases of disease, the choice of available therapies becomes very poor, and the retreatment with previously adopted and effective therapy, although unpredictable, could be an effective option. In this report, we describe the clinical history of a patient, previously treated with 9 lines of therapy, refractory to bortezomib and IMIDs, for whom the retreatment with bendamustine resulted in a stable disease with good quality of life.

Published
2016

17. Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma

Author

Silvana Del Vecchio, Serena De Luca, Marco Salvatore, Michele Larobina, Rossella Fabbricini, Rosa Fonti, Fabrizio Pane, Lucio Catalano, Leonardo Pace, Fonti, R, Larobina, M, DEL VECCHIO, Silvana, DE LUCA, Serena, Fabbricini, R, Catalano, Lucio, Pane, Fabrizio, Salvatore, Marco, and Pace, L.

Subjects
Adult, Male, 18F-FDG-PET/CT, Standardized uptake value, Multimodal Imaging, Lesion, Multiple myeloma, Metabolic tumor volume, Prognosis, Fluorodeoxyglucose F18, parasitic diseases, medicine, Humans, Radiology, Nuclear Medicine and imaging, Survival analysis, Aged, Retrospective Studies, Aged, 80 and over, medicine.diagnostic_test, Performance status, business.industry, Middle Aged, medicine.disease, Survival Analysis, Tumor Burden, medicine.anatomical_structure, Positron emission tomography, Positron-Emission Tomography, Female, Bone marrow, medicine.symptom, Tomography, X-Ray Computed, Nuclear medicine, business, Glycolysis, Progressive disease
Abstract

(18)F-FDG PET/CT allows the direct measurement of metabolic tumor burden in a variety of different malignancies. The aim of this study was to assess whether metabolic tumor volume (MTV) determined by (18)F-FDG PET/CT could be used in the prediction of progression-free and overall survival in multiple myeloma patients.Forty-seven patients (18 women, 29 men; mean age ± SD, 63 ± 11 y) with stage IIIA disease who had undergone whole-body (18)F-FDG PET/CT were retrospectively evaluated. Images underwent a 3-dimensional region-of-interest analysis including all focal lesions with a maximum standardized uptake value2.5. The MTV of each lesion was calculated using an automated contouring program based on the standardized uptake value and developed with a threshold of 40% of the maximum standardized uptake value. The total MTV of each patient was defined as the sum of metabolic volume of all focal lesions. Patients were treated and then subjected to a mean follow-up period of 24 mo.In the 47 patients studied, MTV range was 1.3-316.3 mL, with a median of 23.7 mL. A direct, significant correlation was found between MTV and the percentage of diffuse infiltration of bone marrow by plasma cells (r = 0.46, P = 0.006), whereas hemoglobin levels were inversely correlated with MTV (r = -0.56, P = 0.0001). At follow-up, patients who developed progressive disease (n = 18) showed a significantly higher MTV (74.7 ± 19.3 vs. 29.8 ± 5.1 mL, P = 0.009) than patients without progressive disease (n = 29). Furthermore, patients who died of myeloma (n = 9) had a significantly higher MTV (123.2 ± 30.6 vs. 28.9 ± 4.2 mL, P = 0.0001) than survivors (n = 38). No differences in age, plasma cell infiltration, M protein, albumin, β2-microglobulin, performance status, International Staging System score, and presence or absence of a bone marrow transplant were found between groups. The MTV cutoff level was determined by receiver-operating-characteristic curve analysis, and the best discriminative value found for predicting progression-free and overall survival was 42.2 and 77.6 mL, respectively. By Kaplan-Meier analysis and log-rank testing, progression-free and overall survival at follow-up were significantly better in patients showing an MTV lower than the cutoff than in those having an MTV higher than the cutoff (χ(2) = 3.9, P = 0.04, and χ(2) = 56.3, P0.0001, respectively).The direct measurement of tumor burden obtained by calculating MTV on (18)F-FDG PET/CT images may be used in the prediction of progression-free and overall survival in myeloma patients.

Published
2012

18. Bone Scintigraphy and SPECT/CT of Bisphosphonate-Induced Osteonecrosis of the Jaw

Author

Leonardo Pace, Bruno Rotoli, Marco Salvatore, Rossella Fabbricini, Rosa Fonti, Lucio Catalano, Silvana Del Vecchio, Dore, F, Filippi, L, Biasotto, Matteo, Chiandussi, Silvia, Cavalli, Fabio, DI LENARDA, Roberto, Fabbricini, R, Catalano, Lucio, Pace, Leonardo, DEL VECCHIO, Silvana, Fonti, R, Salvatore, Marco, and Rotoli, B.

Subjects
Male, medicine.medical_specialty, Technetium Tc 99m Medronate, Radiography, medicine.medical_treatment, Scintigraphy, jaw, bone scintigraphy, SPECT/CT, osteonecrosis, Radiography, Panoramic, medicine, Humans, Radiology, Nuclear Medicine and imaging, Multiple myeloma, Aged, Aged, 80 and over, Tomography, Emission-Computed, Single-Photon, Diphosphonates, medicine.diagnostic_test, business.industry, Mandible, Magnetic resonance imaging, Middle Aged, Bisphosphonate, medicine.disease, Magnetic Resonance Imaging, Zoledronic acid, Bone scintigraphy, Female, Tomography, Radiology, Nuclear medicine, Tomography, X-Ray Computed, business, Osteonecrosis of the jaw, medicine.drug
Abstract

Endovenous bisphosphonate therapy seems associated with osteonecrosis of the jaw. The aim of this study was to evaluate the additional diagnostic value of hybrid SPECT/CT in 99m Tc-methylene diphosphonate 3-phase bone scintigraphy of osteonecrosis of the jaw in bisphosphonate-treated patients. Methods: We studied 15 patients (12 women and 3 men) with extraoral tumors affected by lytic bone metastases and multiple myeloma. All patients were previously treated with intravenous bisphosphonates (zoledronic acid) for 1–3 y, were negative for dental disease at clinical examination, and had suspected osteonecrosis of the jaw. All 15 patients underwent panoramic x-ray orthopantomography, CT or MRI (or both), microbiologic examination, 3-phase bone scintigraphy, and SPECT/CT of the maxillary region. Results: Three-phase bonescintigraphy showed increased perfusion and an increased blood pool in 9 of 12 and 10 of 12 patients, respectively; at the metabolic phase, SPECT was positive in all patients and showed abnormal hyperactivity in the maxilla of 2 patients, in the mandible of 9 patients, and in both the mandible and the maxilla of 4 patients. Hybrid SPECT/CT was of particular value in 8 of 15 patients, allowing discrimination of the osteonecrotic core from nearby hyperactivity due to viable bone. Whole-body scintigraphy showed remote and multiple metastases in all patients. Orthopantomography showed nonspecific bone rarefaction in all patients but was not able to aid diagnosis of osteonecrosis of the jaw. CT and MRI showed anomalies in all symptomatic patients: CT was helpful in evaluating both cortical and trabecular bone aspects, and MRI was able to detect soft-tissue involvement but not cortical bone destruction. Conclusion: In appropriately selected oncology patients treated with bisphosphonates, an increased uptake of 99m Tc-methylene diphosphonate in maxillary bones may suggest probable osteonecrosis of the jaw. In such cases, SPECT/CT may be of value in increasing the diagnostic accuracy of bone scanning, providing a precise functional anatomic correlation for the definition of the extent of disease.

Published
2008

19. Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience

Author

Anna Emanuele Pareto, Fabrizio Pane, Marco Picardi, Lucio Catalano, Claudio Cerchione, Cerchione, Claudio, Catalano, Lucio, Pareto, ANNA EMANUELE, Picardi, Marco, and Pane, Fabrizio

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Filgrastim, medicine.medical_treatment, Antineoplastic Agents, Polyethylene Glycols, Life Change Events, Antineoplastic Agent, Primary prevention, Internal medicine, Granulocyte Colony-Stimulating Factor, medicine, Humans, Aged, Febrile Neutropenia, Aged, 80 and over, Chemotherapy, business.industry, Medicine (all), Refractory Multiple Myeloma, Life Change Event, Middle Aged, Recombinant Protein, medicine.disease, Recombinant Proteins, Primary Prevention, Female, business, Multiple Myeloma, Febrile neutropenia, Pegfilgrastim, medicine.drug, Human
Published
2015

20. Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myeloma

Author

Eugenio Piro, Pellegrino Musto, Fabrizio Pane, Rosanna Ciancia, Giulia Vita, Laura Virginia Sosa Fernandez, Lucio Catalano, Immacolata Cozzolino, Giuseppe Ciancia, Fiorella D'Auria, Fortunato Morabito, Pio Zeppa, Maria Rita Costanza Ponti, Guido Pettinato, Fara Petruzziello, Mariarosaria Cervasio, Petruzziello, F, Zeppa, P, Ciancia, G, Cozzolino, I, Fernandez, L, Cervasio, M, Musto, P, D'Auria, F, Vita, G, Morabito, F, Piro, E, Ponti, Mr, Pettinato, G, Ciancia, R, Pane, Fabrizio, and Catalano, Lucio

Subjects
Adult, Male, Cancer Research, Pathology, medicine.medical_specialty, Amyloid, Plaque, Amyloid, Immunoglobulin Light-chain Amyloidosis, Bone Marrow, Biopsy, Humans, Medicine, Iliac spine, Multiple myeloma, Aged, Retrospective Studies, Aged, 80 and over, medicine.diagnostic_test, business.industry, Biopsy, Needle, Hematology, Middle Aged, medicine.disease, Systemic amyloidosis, medicine.anatomical_structure, Oncology, Female, Bone marrow, Multiple Myeloma, business, Core biopsy
Abstract

We recently published a study aiming to verify the frequency of amyloid deposits in the bone marrow of patients with multiple myeloma (MM) who did not present any signs or symptoms of systemic amyloidosis, applying the Congo red technique on bone marrow smears obtained by aspiration from the posterior iliac spine. The results suggested that nearly 40% of patients affected by MM may have amyloid deposits in their bone marrow. Subsequently, this finding has not been confirmed by another study performed with histological specimens of bone marrow in a similar clinical setting. To explain this discrepancy, we performed a comparative study on the bone marrows of 36 patients affected by MM, evaluated by both cytological and histological techniques. The results of this study confirm the high frequency of amyloid deposits in the bone marrow of patients affected by MM when the analysis is made on cytological smears, and indicate that the presence of amyloid on marrow smears is confirmed by core biopsies simultaneously performed in only 25% of cases. Should further studies confirm our findings, cytological assessment could be considered a sensitive technique to detect bone marrow amyloid deposits.

Published
2011

21. Amyloid in bone marrow smears of patients affected by multiple myeloma

Author

Eugenio Piro, Salvatore Tafuto, Giuseppe Gargiulo, Lucio Catalano, Antonietta Falcone, Fiorella D'Auria, Michelino De Laurentiis, Nadia Caruso, Bruno Rotoli, Rita Rizzi, Fara Petruzziello, Pio Zeppa, Catello Califano, Fabrizio Pane, Francesco Di Raimondo, Immacolata Cozzolino, Maurizio Musso, Pellegrino Musto, Lucio Palombini, Vincenza Bonanno, Vincenzo Liso, Hematology, Department of Biochemistry and Medical Biotechnology, Università degli studi di Napoli Federico II, Department of Anatomopathology and Cytopathology, Department of Hematology, Stazione Zoologica Anton Dohrn (SZN), Hematology and Stem Cell Transplantation Unit, IRCCS, Hematology, AOUCP Bari, Hematology Unit, Annunziata Hospital, Department of Oncology and Hematology, PO Umberto I, Hematology Unit, AO Pugliese-Ciaccio, Oncohematology Unit, Oncology Department La Maddalena, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Casa Sollievo della Sofferenza [San Giovanni Rotondo] (IRCCS), Oncohematology, PO S.Maria delle Grazie, AO Ferrarotto, Department of Endocrinology and Clinical Oncology, Petruzziello, F, Zeppa, Pio, Catalano, Lucio, Cozzolino, I, Gargiulo, G, Musto, P, D'Auria, F, Liso, V, Rizzi, R, Caruso, N, Califano, C, Piro, E, Musso, M, Bonanno, V, Pia Falcone, A, Tafuto, S, Di Raimondo, F, De Laurentiis, M, Pane, Fabrizio, Palombini, Lucio, Rotoli, Bruno, Stazione Zoologica Anton Dhorn, and IRCCS Casa Sollievo della Sofferenza

Subjects
Amyloid, medicine.medical_specialty, Pathology, Time Factors, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, Multiple myeloma, Internal medicine, medicine, AL amyloidosis, Humans, Retrospective Studies, multiple myeloma, Hematology, Staining and Labeling, Bortezomib, business.industry, Amyloidosis, Bone marrow amyloid, bone marrow smear, Congo Red, General Medicine, Congo red staining, medicine.disease, 3. Good health, Peripheral neuropathy, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Bone marrow, business, Amyloidosis, Multiple myeloma, Congo red staining, Bone marrow amyloid, Follow-Up Studies, 030215 immunology, medicine.drug
Abstract

International audience; Systemic AL amyloidosis is associated with nearly 15% of cases of multiple myeloma, but data on the frequency and significance of amyloid deposits in the bone marrow of patients affected by multiple myeloma without clinical signs of systemic amyloidosis are scanty. Bone marrow smears of 166 unselected patients affected by multiple myeloma (126 at diagnosis and 40 after treatment) were stained with Congo red and studied by transmission and birefringence microscopy. Both focal and diffuse storages were considered positive. Overall, 67 patients were positive and 99 were negative to Congo red and apple-green birefringence. In particular, 51 of the 126 patients studied at diagnosis and 16 of the 40 patients with advanced disease were positive. Seventeen patients were reassessed after a mean follow-up of 32 months (range: 6–91): disappearance of amyloid deposits was verified in three cases, all responsive to bortezomib-based regimens. The preliminary data available suggest that amyloid deposition in the marrow of myeloma patients is frequent, as it can be traced in nearly 40% of cases. We failed to find correlations between bone marrow amyloid deposits and immunoglobulin type, disease stage, plasma cells percentage, hemoglobin, calcium, creatinine, albumin, or βmicroglobulin. Significantly higher incidence of moderate/severe peripheral neuropathy was found in patients with marrow amyloid exposed to potentially neurotoxic antineoplastic agents. Further studies and prolonged follow-up are needed to validate our findings and to define possible prognostic aspects.

Published
2010

22. Detection of increased left ventricular filling pressure by pulsed tissue Doppler in cardiac amyloidosis

Author

Maria Carmen Martorelli, Bruno Rotoli, Marinella Olibet, Maurizio Galderisi, Moira Pardo, Lucio Catalano, Oreste de Divitiis, Pasquale Innelli, Innelli, Pasquale, Galderisi, Maurizio, Catalano, Lucio, Martorelli, Maria Carmen, Olibet, Marinella, Pardo, Moira, Rotoli, Bruno, and De Divitiis, Oreste

Subjects
Male, medicine.medical_specialty, Heart Diseases, Population, Diastole, Doppler echocardiography, Sensitivity and Specificity, Cohort Studies, Ventricular Dysfunction, Left, Left ventricular filling pressure, Internal medicine, Heart rate, medicine, Amyloidosi, Humans, education, Aged, Probability, Echocardiography, Doppler, Pulsed, education.field_of_study, Analysis of Variance, medicine.diagnostic_test, business.industry, Stroke Volume, Amyloidosis, General Medicine, Stroke volume, Middle Aged, Echocardiography, Doppler, Color, Blood pressure, Heart Disease, Cardiac amyloidosis, Linear Models, Cardiology, Linear Model, Female, Tissue Doppler, Cohort Studie, business, Cardiology and Cardiovascular Medicine, Body mass index, Monte Carlo Method, Human
Abstract

The aim of this study was to evaluate the incremental diagnostic role of tissue Doppler in primary cardiac amyloidosis (CA).Eleven patients with CA at diagnosis and 11 healthy controls, matched for sex and age, underwent standard Doppler echocardiography and pulsed tissue Doppler of the left ventricular (LV) lateral annulus, in the apical four-chamber view. The ratio of early transmitral flow velocity to early diastolic mitral annular velocity (E/E(m) ratio) was derived as an index of LV filling pressure.The two groups were comparable for body mass index, blood pressure, heart rate and standard Doppler diastolic measurements. Patients with CA had a significantly higher sum of wall thickness (SWT) and LV mass, a lower E(m) peak velocity (P0.002) and a higher E/E(m) ratio (P0.001) than controls. By dividing CA patients according to the transmitral E/A ratio, patients with an E/A ratio1 (abnormal relaxation) (n = 5) and patients with an E/A ratio1 (likely pseudonormal/restrictive pattern) (n = 6) did not show any difference in the E/E(m) ratio (14.5 + or - 7.1 vs. 15.1 + or - 6.4, P = NS). In the overall population, the E/E(m) ratio was related to SWT (r = 0.84, P0.0001) and LV mass index (r = 0.72, P0.0001). After adjusting for age and heart rate by separate multivariate models, SWT (beta = 0.78, P0.0001; cumulative r(2) = 0.63, SE = 3.38, P0.0001) and LV mass index (beta = 0.71, P0.0001; cumulative r(2) = 0.53, SE = 3.80, P0.002) were both independently associated with the E/E(m) ratio.Pulsed tissue Doppler is able to detect early myocardial diastolic impairment in CA. The E/E(m) ratio is very useful in diagnosing increased LV filling pressure, regardless of the transmitral pattern, and may, therefore, be helpful in the clinical management of these patients.

Published
2006

23. Bone Marrow uptake of 99mTc-MIBI in patients with multiple myeloma

Author

Lucio Catalano, Marco Salvatore, Catello Califano, S. Del Vecchio, A De Renzo, Antonella Zannetti, Rosa Fonti, F Di Gennaro, Leonardo Pace, Bruno Rotoli, Fonti, R, DEL VECCHIO, S, Zannetti, A, DE RENZO, A, DI GENNARO, F, Catalano, L, Califano, C, Pace, Leonardo, Rotoli, B, Salvatore, M., Fonti, R., DEL VECCHIO, L., Zannetti, A., DE RENZO, A., DI GENNARO, A., Catalano, L., Califano, C., Pace, L., Rotoli, Bruno, Salvatore, F., DEL VECCHIO, Silvana, DE RENZO, Amalia, Catalano, Lucio, Pace, L, and Salvatore, Marco

Subjects
Male, Technetium Tc 99m Sestamibi, Pathology, medicine.medical_specialty, Plasma Cells, Bone Marrow Cells, Plasma cell, Scintigraphy, Whole-Body Counting, In vivo, Bone Marrow, Blood plasma, medicine, Humans, Radiology, Nuclear Medicine and imaging, Radionuclide Imaging, Cellular localization, Multiple myeloma, Aged, medicine.diagnostic_test, business.industry, General Medicine, Middle Aged, medicine.disease, medicine.anatomical_structure, Autoradiography, Female, Bone marrow, Radiopharmaceuticals, business, Nuclear medicine, Multiple Myeloma, Monoclonal gammopathy of undetermined significance
Abstract

In a previous study, we showed the ability of technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) scan to identify active disease in patients with multiple myeloma (Eur J Nucl Med 1998; 25: 714–720). In particular, a semiquantitative score of the extension and in- tensity of bone marrow uptake was derived and correlated with both the clinical status of the disease and plasma cell bone marrow infiltration. In order to estimate quantitatively 99mTc-MIBI bone marrow uptake and to verify the intracellular localization of the tracer, bone marrow samples obtained from 24 multiple myeloma patients, three patients with monoclonal gammopathy of undetermined significance (MGUS) and two healthy donors were studied for in vitro uptake. After centrifugation over Ficoll-Hypaque gradient, cell suspensions were in- cubated with 99mTc-MIBI and the uptake was expressed as the percentage of radioactivity specifically retained within the cells. The cellular localization of the tracer was assessed by micro-autoradiography. Twenty-two out of 27 patients underwent 99mTc-MIBI scan within a week of bone marrow sampling. Whole-body images were ob- tained 10 min after intravenous injection of 555 MBq of the tracer; the extension and intensity of 99mTc-MIBI uptake were graded using the semiquantitative score. A statistically significant correlation was found between in vitro uptake of 99mTc-MIBI and both plasma cell infil- tration (Pearson's coefficient of correlation r=0.69, P

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results